



## A new 3, 4-epoxyfurocoumarin from *Heracleum moellendorffii* Roots

Sang Yeol Park<sup>1,†</sup>, Nara Lee<sup>1,†</sup>, SunKyoung Lee<sup>1,†</sup>, Myong Jo Kim<sup>2</sup>, Wanjoo Chun<sup>3</sup>, Hyun Pyo Kim<sup>1</sup>, Hee Jung Yang<sup>1</sup>, Ho Sun Lee<sup>4</sup>, and Yongsoo Kwon<sup>1,\*</sup>

<sup>1</sup>College of Pharmacy, Kangwon National University, Chuncheon 24341, Korea

<sup>2</sup>College of Agriculture and Life science, Kangwon National University, Chuncheon 24341, Korea

<sup>3</sup>School of Medicine, Kangwon National University, Chuncheon 24341, Korea

<sup>4</sup>Yanggu Agricultural Technology Center, Yanggu 24522, Korea

**Abstract** – Activity-guided isolation of *Heracleum moellendorffii* roots led to four coumarin derivatives as acetylcholinesterase inhibitors. The structures of these isolates were characterized by spectroscopic method to be angelicin (**1**), isobergapten (**2**), pimpinellin (**3**), and (3S, 4R)-3, 4-epoxypimpinellin (**4**). All the isolated compounds **1**, **2**, **3**, and **4** showed moderate inhibition activities against acetylcholinesterase with the IC<sub>50</sub> values of 10.2, 18.1, 21.5 and 22.9 μM, respectively. (3S, 4R)-3, 4-Epoxympinellin (**4**) was newly isolated from the plant source.

**Keywords** – *Heracleum moellendorffii*, Angular furanocoumarins, (3S, 4R)-3, 4-epoxypimpinellin, Acetylcholinesterase inhibition

### Introduction

*Heracleum moellendorffii* is distributed in Korea and China.<sup>1</sup> The roots of this plant has been used as a common cold, headache and analgesics in China.<sup>2</sup> Young and Tender aerial parts of this plant has been used as an edible vegetable in Korea. Coumarins,<sup>3,4</sup> flavonoids,<sup>5</sup> polyacetylenes<sup>6</sup> and essential oils<sup>7</sup> have been isolated from this plant, possessing anti-inflammatory activity, peroxynitrite-scavenging effect, and antiproliferative activity. To the best of our knowledge the acetylcholinesterase inhibitory activity of *Heracleum moellendorffii*, though it is a good source of coumarins, has not been reported, meanwhile some *Heracleum* species has been reported on their anticholinesterase activity.<sup>8-10</sup> Therefore, we focused on the isolation of acetylcholinesterase inhibitors from the roots of *H. moellendorffii*. This study deals with isolation, structure elucidation and determination of acetylcholinesterase inhibitory activity of compounds from the roots of *H. moellendorffii*.

### Experimental

**General experimental procedures** – Melting point was determined using a Fisher-Johns melting point apparatus (uncorrected) (Fisher-Johns, USA), UV/Vis spectra were recorded using a V-530 spectrophotometer (JASCO, Tokyo, Japan). MS spectra were measured using an API 3200 LC/MS/MS system (AB Sciex, Concord, Canada) and JMS-700 (JEOL, Tokyo, Japan). NMR spectra were recorded using a Bruker AVANCE 600 (Bruker, Rheinstetten, Germany). The chemical shifts are represented as parts per million (ppm) using the residual solvent signal as an internal standard. Optical rotation was recorded using a DIP-1000 digital polarimeter (JASCO, Tokyo, Japan). CD spectrum was recorded using a Chirascan ECD spectrometer (Applied Photophysics, Leatherhead, UK). Column chromatography was carried out using a Kieselgel 60, 63 - 200 μm and 40 - 63 μm (Merck, Darmstadt, Germany) and YMC gel ODS-A, 150 μm (YMC, Kyoto, Japan). Flash column chromatography was carried out using CombiFlash®, Retrieve™ (Teledyne Isco Inc., NE, USA). Medium pressure liquid chromatography was carried out using a Buchi 682 chromatography pump system (Buchi, Flawil, Switzerland). TLC was performed on a glass backed Kieselgel 60 F<sub>254</sub> and RP F<sub>254s</sub> plates. All other chemicals and reagents used were of analytical grade. Electric eel acetylcholinesterase, acetylthiocholine

\*Author for correspondence

Yongsoo Kwon, College of Pharmacy, Kangwon National University, Chuncheon, 24341, Korea  
Tel: +82-033-259-5631; E-mail: yskwon@kangwon.ac.kr

†These authors contributed equally to this work.

iodide, and 5,5-thiobis-2-nitrobenzoic acid (DTNB) were purchased from Sigma (St. Louis, Mo, USA.).

**Plant materials** – The roots of *Heracleum moellendorffii* were collected at the Yanggu agricultural technology center, Yanggu, Korea in September, 2015 and identified by professor Yongsoo Kwon (College of Pharmacy, Kangwon National University). A voucher specimen (KNUH-R-1509-1) was deposited in the Herbarium of College of Pharmacy, Kangwon National University, Korea.

**Extraction and isolation** – The air dried roots of *Heracleum moellendorffii* was meshed into the rough powder and extracted with hot MeOH (1.4 kg, 3 L × 3) for 4hrs. The extracts were combined and concentrated *in vacuo* at 40 °C. The MeOH extract (179 g) was suspended in water and successively partitioned with *n*-hexane, CHCl<sub>3</sub>, and *n*-BuOH, leaving a residual water soluble fraction. Each soluble fraction was evaporated *in vacuo* to yield the residues of *n*-hexane fraction (fr.) (19.9 g), CHCl<sub>3</sub> fr. (16.9 g), and *n*-BuOH fr. (15.4 g). Among the extract and solvent soluble fractions, the CHCl<sub>3</sub> fraction showed an acetylcholinesterase inhibitory activity with IC<sub>50</sub> value of 63.1 µg/mL. Among the three fractions, *n*-hexane and CHCl<sub>3</sub> fraction showed very similar patterns by TLC analysis. These two fractions were combined and purified by various chromatography. Two fractions (35 g) were applied to silica gel column (63 - 200 µm, 10 × 50 cm, 1.0 kg) using stepwise gradient elution with *n*-hexane : EtOAc (4:1 → 3:1 → 2:1; 2 L each), to divide it into five fractions (Fr. 1 – Fr. 5). Fr. 3 (12.8 g) was applied to ODS medium pressure liquid chromatography (Buchi 680 pump; 45 × 5 cm; 400 g) using an isocratic elution with MeOH : H<sub>2</sub>O (65 : 35) to yield ten sub-fractions (Fr. 3-1 –

Fr. 3-10). Fr. 3-1 was further purified by *n*-hexane-EtOA to give compound **1** (300 mg). Fr. 3-3 (1.2 g) was applied to normal phase flash column chromatography (RediSep®, 80 g) using an isocratic elution with CHCl<sub>3</sub> : MeOH (99 : 1) to yield four sub-fractions (Fr. 3-3-1 – Fr. 3-3-4). Fr. 3-3-1 (0.7 g) was applied to silica gel column chromatography (40 - 63 µm, 100 g, 3 × 20 cm) using isocratic elution with CHCl<sub>3</sub> to give compounds **2** (170 mg) and **3** (580 mg). Fr. 3-9 (4.3 g) was applied to silica gel column chromatography (40 - 63 µm, 80 g, 3 × 40 cm) using isocratic elution with CHCl<sub>3</sub> : MeOH (19:1) to yield four sub-fractions (Fr. 3-9-1 – Fr. 3-9-4). Fr. 3-9-2 (2.4 g) was re-chromatographed on a silica gel (40 - 63 µm, 100 g, 3 × 20 cm) using elution with *n*-hexane : EtOAc (4:1) to yield four sub-fractions (Fr. 3-9-2-1 – Fr. 3-9-2-4). Fr. 3-9-2-3 (0.5 g) was purified by Sephadex LH20 using isocratic elution with MeOH : H<sub>2</sub>O (70:30) to give compound **4** (197 mg).

Compound **1** – <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) δ : 7.82 (1H, d, *J*= 9.5 Hz, H-4), 7.70 (1H, d, *J*= 2.1 Hz, H-2'), 7.45 (1H, d, *J*= 8.6 Hz, H-5), 7.39 (1H, d, *J*= 8.6 Hz, H-6), 7.14 (1H, d, *J*= 2.1 Hz, H-3'), 6.40 (1H, *J*= 9.5 Hz, H-3); <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) δ : see Table 1; ESI-MS (positive mode) *m/z* : 209 [M+H]<sup>+</sup>.


Compound **2** – <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) δ : 8.16 (1H, d, *J*= 9.7 Hz, H-4), 7.57 (1H, d, *J*= 2.2 Hz, H-2'), 7.02 (1H, d, *J*= 2.2 Hz, H-3'), 6.89 (1H, s, H-6), 6.31 (1H, *J*= 9.7 Hz, H-3), 3.97 (3H, s, OCH<sub>3</sub>); <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) δ : see Table 1; ESI-MS (positive mode) *m/z* : 239 [M+H]<sup>+</sup>.

Compound **3** – <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) δ : 8.07 (1H, d, *J*= 9.7 Hz, H-4), 7.65 (1H, d, *J*= 2.0 Hz, H-2'),

**Table 1.** <sup>13</sup>C-NMR data of **1** - **4** (150 MHz, CDCl<sub>3</sub>)

No	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	5,8-dimethoxyetane 3,4-epoxy-furanocoumarin <sup>12</sup>
2	160.89	161.02	160.84	164.69	164.7
3	114.12	112.21	113.72	39.80	37.5
4	144.55	139.89	139.92	38.2	39.1
4a	113.52	105.81	109.44	106.45	107.5
5	123.83	154.27	144.44	147.55	133.8
6	108.83	90.53	135.12	134.56	112.9
7	157.37	157.98	149.80	148.19	147.2
8	116.94	110.06	114.09	113.81	147.4
8a	148.50	148.79	143.17	139.53	139.1
2'	145.89	144.32	145.39	144.58	145.8
3'	104.11	103.73	104.29	103.97	103.4
OCH <sub>3</sub>		56.31	62.38	60.77	60.4
OCH <sub>3</sub>			61.23	60.77	60.4

Chemical shifts are represented parts per million (δ)

**Fig. 1.** Structures of **1 - 4**.


7.07 (1H, d,  $J = 2.0$  Hz, H-3'), 6.36 (1H,  $J = 9.7$  Hz, H-3), 4.13 (3H, s, OCH<sub>3</sub>), 4.03 (3H, s, OCH<sub>3</sub>); <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  : see Table 1; ESI-MS (positive mode)  $m/z$  : 269 [M+H]<sup>+</sup>.

Compound **4** – White needles; mp : 248~250°C;  $[\alpha]_D^{22^\circ\text{C}}$  : -1.8° (c 1.0, CHCl<sub>3</sub>); CD (c 0.1, CHCl<sub>3</sub>)  $\lambda_{\text{max}} (\Delta\epsilon)$  : 238 (0.25), 210 (-0.36); UV (MeOH,  $\lambda_{\text{max}}$ , log  $\epsilon$ ) nm : 225 (3.34), 253 (s, 2.55), 289 (0.55); IR (ATR,  $\nu_{\text{max}}$ ) cm<sup>-1</sup>: 1756 (C=O), 1480, 1406, 1360 (C=C), 1215, 120, 1046 (C-O); <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  : 7.47 (1H, d,  $J = 2.1$  Hz, H-2'), 6.75 (1H, d,  $J = 2.1$  Hz, H-3'), 4.40 (1H,  $J = 9.6$  Hz, H-4), 4.04 (1H, d,  $J = 9.6$  Hz, H-3), 3.85 (3H, s, OCH<sub>3</sub>), 3.69 (3H, s, OCH<sub>3</sub>); <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  : see Table 1; HR-EI-MS  $m/z$  : 262.0474 (calcd for C<sub>13</sub>H<sub>10</sub>O<sub>6</sub>, 262.0477); EI-MS (rel. int. %)  $m/z$  : 262 (M<sup>+</sup>, 0.22), 246 (100), 231 (99.79), 216 (8.05), 203 (12.99), 188 (15.13), 175 (23.76), 160 (25.50), 147 (30.78), 132 (7.11), 119 (7.26), 109 (3.00), 104 (9.66), 91 (7.59), 76 (5.28).

**Determination of acetylcholinesterase inhibitory activity** – The acetylcholinesterase inhibition assay was measured according to the method of Ellman *et. al.*<sup>11</sup> with slight modification.

## Result and Discussion

Compounds **1**, **2**, and **3** were identified as angelicin,<sup>3</sup> isobergapten,<sup>3</sup> and pimpinellin,<sup>9</sup> respectively, by comparing their physico-chemical and spectral data with those of literature values. The <sup>1</sup>H-NMR spectrum of **4** exhibited two pairs of doublets at  $\delta$  7.47 and 6.75 (each 1H,  $J = 2.1$  Hz), and  $\delta$  4.40 and 4.04 (each 1H,  $J = 9.6$  Hz). Two methoxyl signals showed at  $\delta$  3.85 and 3.69. These signals are very similar to those of 5, 8-dimethoxyetane 3, 4-epoxy-furanocoumarin.<sup>12</sup> The <sup>13</sup>C-NMR and HMBC spectra of **4** were slightly different to that of 5, 8-dimethoxyetane 3, 4-epoxyfuranocoumarin. In the HMBC spectrum of **4**, C-3' proton at  $\delta_H$  6.75 correlated to C-2' carbon at  $\delta_C$  144.58 and C-7 carbon at  $\delta_C$  148.19, C-8 carbon at  $\delta_C$  113.81, and C-8a carbon at  $\delta_C$  139.53. The C-4 proton at  $\delta_H$  4.40 correlated to C-2 carbon at  $\delta_C$

**Fig. 2.** Important HMBC correlations of **4**.**Table 2.** Acetylcholinesterase inhibitory activity of compounds **1 - 4**.

Tested compounds	IC <sub>50</sub> <sup>a)</sup> ( $\mu\text{g/ml}$ )	IC <sub>50</sub> ( $\mu\text{M}$ )
<b>1</b>	1.9	10.2
<b>2</b>	3.9	18.1
<b>3</b>	5.3	21.5
<b>4</b>	6.0	22.9
Eserine <sup>b)</sup>	0.007	0.03

<sup>a)</sup> The inhibitory activity dose that reduced 50% of acetylcholinesterase activity and expressed as mean of two different experiments.

<sup>b)</sup> A positive control

164.69, C-3 carbon at  $\delta_C$  39.80, C-4a carbon at  $\delta_C$  106.45, and C-8a at  $\delta_C$  139.53. Furthermore, the two methoxyl groups are attached at C-5 ( $\delta_C$  144.58) and C-6 ( $\delta_C$  134.56), which were assigned by HSQC and HMBC spectra. These result strongly suggested that **4** is an angular furanocoumarin derivative.<sup>13,14</sup> The HR-EIMS spectrum showed a molecular ion peak at  $m/z$  262.0474, consistent with C<sub>13</sub>H<sub>10</sub>O<sub>6</sub> (calcd for 262.0477). The large coupling constants ( $J = 9.6$  Hz) between H-3 and H-4 showed a 3, 4 – *trans* configuration of **4**. The CD spectrum of **4** showed a positive cotton effect at 238 nm and a negative cotton effect at 210 nm, respectively. These data indicated 4 $\beta$ -oriented epoxy moiety.<sup>15,16</sup> Based on the above data, the absolute configuration of C-3 and C-4 could be determined as 3S, 4R. Thus, the structure of **4** identified as (3S, 4R)-3,4-epoxypimpinellin, which is newly isolated from the plant sources. All the isolated compounds **1**, **2**, **3**, and **4** were tested for acetylcholinesterase inhibition activity, showing inhibition activities against acetylcholinesterase with the IC<sub>50</sub> values of 10.2, 18.1, 21.5 and 22.9

$\mu\text{M}$ , respectively. Though the number of tested compounds is too small, this result suggested that the methoxyl group and 3, 4-epoxy moiety did not affect the acetylcholinesterase inhibitory activity, indicating that  $\alpha$ -pyrone may has a key role against the acetylcholinesterase inhibitory activity in the angular furanocoumarins.

In conclusion, angelicin (**1**), isobergapten (**2**), pimpinellin (**3**), and (*3S*, *4R*) - 3, 4-epoxypimpinellin (**4**) were isolated from the *n*-hexane and chloroform soluble fractions of *H. moellendorffii* roots as acetylcholinesterase inhibitors. (*3S*, *4R*) - 3, 4-Epoxympimpinellin (**4**) was newly isolated from the plant source. All the isolated compounds showed mild acetylcholinesterase inhibitory activity. These results suggested that the extract of root of *H. moellendorffii* might to be a good resource for angular furanocoumarins as acetylcholinesterase inhibitors.

### Acknowledgement

This study was supported by Kangwon National University (No. 520160316) and parts of intensified research programme for undergraduate student of College of Pharmacy, Kangwon National University.

### References

- (1) Lee, W. T. Standard illustrations of Korean plants; Academy Pub. Co.: Seoul, **1996**, p 254.
- (2) Zhong, H. B. C. Editorial Committee of Zhong Hua Ben Cao of State Administration of Traditional Chinese Medicine of People's Republic of China Vol. 5; Shanghai Science and Technology Press; Shanghai, **1999**, pp 960-962.
- (3) Kwon, Y. S.; Cho, H. Y.; Kim, C. M. *Yakhak Hoeji* **2000**, *44*, 521-527.
- (4) Bae, D. S.; Kim C. Y.; Lee, J. K. *Int. Immunopharmacol.* **2012**, *14*, 734-739.
- (5) Park, H. J.; Nugroho, A.; Jung, B.; Won, Y. H.; Jung, Y. J.; Kim, W. B.; Choi, J. S. *Koran J. Plant Res.* **2010**, *23*, 393-398.
- (6) Nakano, Y.; Matsuaga, H.; Saita, T.; Mori, M.; Katano, M.; Okabe, H. *Biol. Pharm. Bull.* **1998**, *21*, 257-261.
- (7) Li, W.; Chen, L.; Wu, C.; Xin, J. *Asian J. Chem.* **2013**, *25*, 4701-4702.
- (8) Orhan, I. E.; Tosun, F.; Skalicka-Woźniak, K. S. *J. Serb. Chem. Soc.* **2016**, *81*, 357-368.
- (9) Dincel, D.; Hatipoğlu, S. D.; Gören, A. C.; Topcu, G. *Turk. J. Chem.* **2013**, *37*, 675-683.
- (10) Orhan, I.; Tosun, F.; Sener, B. Z. *Naturforsch. C* **2008**, *63*, 366-370.
- (11) Ellman, G. L.; Courtney, K. D.; Andres Jr., V.; Feather-stone, R. M. *Biochem. Pharmacol.* **1961**, *7*, 88-95.
- (12) Liu, S.; Zhang, W.; He, G.; Lei, P.; Li, X.; Liang, Y. *Zhongguo Zhongyao Zazhi* **2009**, *34*, 571-573.
- (13) Steck, W.; Mazurek, M. *Lloydia* **1972**, *35*, 418-439.
- (14) Luz, R. F.; Vieira, I. J. C.; Braz-Filho, R.; Moreira, V. F. *Am. J. Analys. Chem.* **2015**, *6*, 851-866.
- (15) De Angelis, G. G.; Wildman, W. C. *Tetrahedron* **1969**, *25*, 5099-5112.
- (16) Dhooghe, L.; Maregesi, S.; Mincheva, I.; Ferreira, D.; Marais, J. P.; Lemière, F.; Mattheussen, A.; Cos, P.; Maes, L.; Vlietinck, A.; Aperes S.; Pieters, L. *Phytochemistry* **2010**, *71*, 785-791.

Received April 11, 2017

Revised June 13, 2017

Accepted June 13, 2017